1252642-90-2

Basic information

• Product Name: 5,5-dimethyl-3-[4-nitro-3-(trifluoromethyl)phenyl]-1-{9-[(4,4,5,5,5-pentafluoropentyl)sulphinyl]nonyl}imidazolidine-2,4-dione
• Synonyms: 5,5-dimethyl-3-[4-nitro-3-(trifluoromethyl)phenyl]-1-{9-[(4,4,5,5,5-pentafluoropentyl)sulphinyl]nonyl}imidazolidine-2,4-dione
• CAS NO: 1252642-90-2
• Molecular Weight: 651.618
• Mol File: 1252642-90-2.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 5,5-dimethyl-3-[4-nitro-3-(trifluoromethyl)phenyl]-1-{9-[(4,4,5,5,5-pentafluoropentyl)sulphinyl]nonyl}imidazolidine-2,4-dione(CAS DataBase Reference)
• NIST Chemistry Reference: 5,5-dimethyl-3-[4-nitro-3-(trifluoromethyl)phenyl]-1-{9-[(4,4,5,5,5-pentafluoropentyl)sulphinyl]nonyl}imidazolidine-2,4-dione(1252642-90-2)
• EPA Substance Registry System: 5,5-dimethyl-3-[4-nitro-3-(trifluoromethyl)phenyl]-1-{9-[(4,4,5,5,5-pentafluoropentyl)sulphinyl]nonyl}imidazolidine-2,4-dione(1252642-90-2)

Safety Data

• Hazardous Substances Data: 1252642-90-2(Hazardous Substances Data)

Upstream product

• 862700-62-7 methanesulfonic acid 9-(4,4,5,5,5-pentafluoro-pentyl-sulfanyl)-nonyl ester 
• 1252642-89-9 5,5-dimethyl-3-[4-nitro-3-(trifluoromethyl)phenyl]-1-{9-[(4,4,5,5,5-pentafluoropentyl)thio]nonyl}imidazolidine-2,4-dione 

Downstream Products

• 1252643-50-7 N-[(9-{5,5-dimethyl-3-[4-nitro-3-(trifluoromethyl)phenyl]-2,4-dioxoimidazolidin-1-yl}nonyl)(oxido)(4,4,5,5,5-pentafluoropentyl)-λ4-sulphanylidene]-2,2,2-trifluoroacetamide 
• 1252642-91-3 5,5-dimethyl-3-[4-nitro-3-(trifluoromethyl)phenyl]-1-{9-[(4,4,5,5,5-pentafluoropentyl)sulphonyl]nonyl}imidazolidine-2,4-dione 

Relevant articles and documents

IMIDAZOLIDINE-2,4-DIONE DERIVATIVES, AND USE THEREOF AS A CANCER DRUG

The present application relates to novel imidazolidine-2,4-dione derivatives of the general formula (I), where R1, R2, R3, R4, X, and Y are variables. Said materials have an antiproliferative activity. They are particularly useful for treating pathological conditions and diseases, such as cancer, that are linked to abnormal cell proliferation. The invention also relates to pharmaceutical compositions containing said materials and to the use thereof for preparing a drug.